Home » Stocks » ERYP

Erytech Pharma S.A. (ERYP)

Stock Price: $6.51 USD -0.49 (-7.00%)
Updated May 13, 2021 3:19 PM EDT - Market open
Market Cap 176.39M
Revenue (ttm) 4.53M
Net Income (ttm) -89.39M
Shares Out 25.78M
EPS (ttm) -4.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $6.51
Previous Close $7.00
Change ($) -0.49
Change (%) -7.00%
Day's Open 6.96
Day's Range 6.51 - 6.96
Day's Volume 1,679
52-Week Range 5.00 - 13.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1

1 week ago - GlobeNewsWire

ERYTECH Announces $ 30.0 Million Registered Direct Offering

2 weeks ago - GlobeNewsWire

ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call

2 weeks ago - GlobeNewsWire

ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL

3 weeks ago - GlobeNewsWire

ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer

3 weeks ago - GlobeNewsWire

ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

1 month ago - GlobeNewsWire

ERYTECH Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F

2 months ago - GlobeNewsWire

ERYTECH Pharma S.A. (ERYP) has been struggling lately, but the selling pressure may be coming to an end soon

2 months ago - Zacks Investment Research

ERYTECH to Present at the 2021 BIO CEO & Investor Conference

3 months ago - GlobeNewsWire

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

3 months ago - GlobeNewsWire

ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Lyon (France) and Cambridge, MA (U.S.), January 6, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeuti...

4 months ago - GlobeNewsWire

ERYTECH to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

4 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...

4 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...

5 months ago - GlobeNewsWire

LYON, France, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

5 months ago - GlobeNewsWire

W ebcast today, Monday, December 7 at 4:00 pm CET/10:00 am ET

5 months ago - GlobeNewsWire

Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET Webcast scheduled for Monday, December 7 at 4:00 pm CET/10:00 am ET

5 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced t o day that its CEO, Gil Beyen, will present an update at the Jefferies Virtual ...

6 months ago - GlobeNewsWire

ERYTECH Pharma's (ERYP) CEO Gil Beyen on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET

6 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulatin...

6 months ago - GlobeNewsWire

Article 223-16 of general regulation of French Autorité des Marchés Financiers

6 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...

6 months ago - GlobeNewsWire

LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therape...

6 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...

6 months ago - GlobeNewsWire

ERYTECH is progressing a phase 3 trial in pancreatic cancer. The drug, reformulated L-asparaginase, has known anti-cancer properties but its safety profile needs to be good.

6 months ago - Seeking Alpha

Article 223-16 of general regulation of French Autorité des Marchés Financiers

7 months ago - GlobeNewsWire

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q2 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

LYON, France, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating dru...

7 months ago - GlobeNewsWire

LYON, France, Sept. 16, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating thera...

7 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsula...

7 months ago - GlobeNewsWire

LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

7 months ago - GlobeNewsWire

Erytech is a company with a promising novel method targeting the large cancer market with unmet needs.

8 months ago - Seeking Alpha

LYON, France, Aug. 06, 2020 (GLOBE NEWSWIRE) --   Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

9 months ago - GlobeNewsWire

LYON, France, July 10, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

10 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., June 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2020 Annual General Meeting was held in Lyon on Friday, June 2...

10 months ago - GlobeNewsWire

Agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund for the issuance of zero-coupon convertible notes with share warrants attached Agreement with Alpha Blue Ocean ...

10 months ago - GlobeNewsWire

LYON, France, June 09, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

11 months ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., June 09, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulat...

11 months ago - GlobeNewsWire

Erytech Pharma SA Sponsored ADR (ERYP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11 months ago - Zacks Investment Research

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

LYON, France, May 07, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

1 year ago - GlobeNewsWire

Conference call and webcast on Thursday, May 7 at 2:30 pm CET/8:30 am ET

1 year ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulatin...

1 year ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsula...

1 year ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer thera...

1 year ago - GlobeNewsWire

LYON, France, April 20, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing red blood cell-based cancer therapeutics, today  provi...

1 year ago - GlobeNewsWire

LYON, France, April 06, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France

1 year ago - GlobeNewsWire

LYON, France and CAMBRIDGE, Mass., March 19, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsula...

1 year ago - GlobeNewsWire

About ERYP

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-l... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Gil Beyen
Employees
206
Stock Exchange
NASDAQ
Ticker Symbol
ERYP
Full Company Profile

Financial Performance

In 2020, Erytech Pharma's revenue was 3.72 million, a decrease of -29.62% compared to the previous year's 5.28 million. Losses were -73.30 million, 17.0% more than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Erytech Pharma stock is "Strong Buy." The 12-month stock price forecast is 17.96, which is an increase of 175.88% from the latest price.

Price Target
$17.96
(175.88% upside)
Analyst Consensus: Strong Buy